N-(2-amino-6-hydroxyphenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide | 365462-77-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-amino-6-hydroxyphenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide
• 英文别名: 2'-amino-6'-hydroxy-4-(4-methyl-1,4-diazepan-1-yl)benzanilide；N-(2-amino-6-hydroxyphenyl)-4-(1-methylhomopiperazin-4-yl)benzamide
• CAS: 365462-77-7
• 化学式: C₁₉H₂₄N₄O₂
• 分子量: 340.425
• InChiKey: CYKNSDSJYFOOTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  81.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2-amino-6-hydroxyphenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide 在 吡啶 、 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 溶剂黄146 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 96.0h， 生成 4-hydroxy-N-(3-hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)-benzoyl]amino}phenyl)benzamide hydrochloride
  参考文献：
  名称：

  Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor

  摘要：

  Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as a target for developing antithrombotic agents. We previously reported findings from our optimization study of a high-throughput screening (HTS) derived lead compound la that resulted in the discovery of potent amidine-containing FXa inhibitors represented by compound 2. We also conducted an alternative optimization study of la without incorporating a strong basic amidine group, which generally has an adverse effect on the pharmacokinetic profile after oral administration. Replacement of 4-methoxybenzene with a 1,4-benzodiazepine structure and introduction of a hydroxy group at the central benzene led to the discovery of the potent and orally effective factor Xa inhibitor 14i (darexaban, YM150). Subsequent extensive study revealed a unique aspect to the pharmacokinetic profile of this compound, wherein the hydroxy moiety of 141 is rapidly transformed into its glucuronide conjugate 16 (YM-222714) as an active metabolite after oral administration and it plays a major role in expression of potent anticoagulant activity in plasma. The distinctive, potent activity of inhibitor 14i after oral dosing was explained by this unique pharmacokinetic profile and its favorable membrane permeability. Compound 14i is currently undergoing clinical development for prevention and treatment of thromboembolic diseases.

  DOI：

  10.1021/jm200868m
• 作为产物：
  描述：

  2-氨基-3-硝基苯酚 在 吡啶 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 5.0~70.0 ℃ 、101.33 kPa 条件下， 反应 41.0h， 生成 N-(2-amino-6-hydroxyphenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide
  参考文献：
  名称：

  Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor

  摘要：

  Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as a target for developing antithrombotic agents. We previously reported findings from our optimization study of a high-throughput screening (HTS) derived lead compound la that resulted in the discovery of potent amidine-containing FXa inhibitors represented by compound 2. We also conducted an alternative optimization study of la without incorporating a strong basic amidine group, which generally has an adverse effect on the pharmacokinetic profile after oral administration. Replacement of 4-methoxybenzene with a 1,4-benzodiazepine structure and introduction of a hydroxy group at the central benzene led to the discovery of the potent and orally effective factor Xa inhibitor 14i (darexaban, YM150). Subsequent extensive study revealed a unique aspect to the pharmacokinetic profile of this compound, wherein the hydroxy moiety of 141 is rapidly transformed into its glucuronide conjugate 16 (YM-222714) as an active metabolite after oral administration and it plays a major role in expression of potent anticoagulant activity in plasma. The distinctive, potent activity of inhibitor 14i after oral dosing was explained by this unique pharmacokinetic profile and its favorable membrane permeability. Compound 14i is currently undergoing clinical development for prevention and treatment of thromboembolic diseases.

  DOI：

  10.1021/jm200868m

文献信息

• [EN] BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DERIVES DE BENZAMIDE UTILES EN TANT QU'INHIBITEURS D'HISTONE DEACETYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2003087057A1

  公开（公告）日：2003-10-23

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.

  本发明涉及一种公式(I)的化合物，其中环A是杂环；m为0-4，每个R1是如羟基、卤素、三氟甲基和腈的基团；R2是卤素，n为0-2；每个R4是如羟基、卤素、三氟甲基和腈的基团；p为0-4；R3是氨基或羟基；或其药物可接受的盐或体内可水解的酯或酰胺及其制备过程，包含它们的药物组合物以及它们在治疗由组蛋白脱乙酰酶介导的疾病或医疗条件中的用途。
• Diazepane derivatives or salts thereof
  申请人：——

  公开号：US20030195193A1

  公开（公告）日：2003-10-16

  To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.

  提供一种基于抑制活化的血液凝血因子X而具有抗凝作用的化合物，可用作抗凝剂或预防和治疗由血栓或栓塞引起的疾病的药物。4-[(3-羧基胍基苯基氨基)甲基]-3-[4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲酰氨基]苯甲酸和3-羟基-4′-甲氧基-2-{[4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲酰]氨基}苯甲酰胺或其盐是有效成分。
• Diazepan derivatives or salts thereof
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：US20040068109A1

  公开（公告）日：2004-04-08

  To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.

  提供一种化合物，其基于抑制活化的血液凝血因子X具有抗凝作用，并可用作抗凝剂或预防和治疗由血栓或栓子引起的疾病的药物。一种苯二氮平衍生物，例如4-[(3-氨基甲酰苯基)氨基甲基]-3-[(4-甲基-1,4-二氮平-1-基)苯甲酰氨基]苯甲酸和3-羟基-4'-甲氧基-2-[4-(4-甲基-1,4-二氮平-1-基)苯甲酰]氨基}苯甲酰苯胺或其盐是有效成分。
• Benzamide derivatives useful as histone deacetylase inhibitors
  申请人：Stokes Sophie Elizabeth Elaine

  公开号：US20050171103A1

  公开（公告）日：2005-08-04

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R 1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R 2 is, halo and n is 0-2; and each R 4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R 3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.

  本发明涉及一种化合物，其化学式为（I），其中环A为杂环基；m为0-4，每个R1是羟基、卤素、三氟甲基和氰基等基团；R2为卤素，n为0-2；每个R4是羟基、卤素、三氟甲基和氰基等基团；p为0-4；R3为氨基或羟基；或其药学可接受的盐或体内可水解的酯或酰胺，以及制备它们的过程，含有它们的制药组合物以及它们在治疗组织脱乙酰化酶介导的疾病或医学状况中的用途。
• BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS
  申请人：Stokes Elaine Sophie Elizabeth

  公开号：US20090029991A1

  公开（公告）日：2009-01-29

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R 1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R 2 is halo and n is 0-2; and each R 4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R 3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by histone deacetylase.

  本发明涉及式（I）的化合物，其中环A是杂环基；m为0-4，每个R1是羟基、卤素、三氟甲基和氰基等基团；R2是卤素，n为0-2；每个R4是羟基、卤素、三氟甲基和氰基等基团；p为0-4；R3是氨基或羟基；或其药学上可接受的盐或体内可水解的酯或酰胺，其制备方法，含有它们的制药组合物以及它们在通过组蛋白去乙酰化酶介导的疾病或医学情况的治疗中的应用。